珠海中富(000659.SZ)第三季度預盈0.8億-1億元 同比增長864%-1105%
格隆匯10月14日丨珠海中富(000659.SZ)公佈,預計2021年前三季度歸屬於上市公司股東的淨利潤1億元-1.2億元,上年同期虧損1652萬元;其中,第三季度歸屬於上市公司股東的淨利潤0.8億元-1億元,同比增長864%-1105%。業績變動原因如下:
1、對比去年同期,報吿期內隨着國內新冠肺炎疫情得到有效控制,公司及公司上下游企業基本恢復正常運營,公司大力拓展新業務,優化產品結構,有效控制費用成本,銷售收入及毛利率均較去年同期有所增長,業績有較大提升。
2、2021年第三季度公司位於珠海保税區的生活區配套用地被政府收儲,為公司帶來較大的資產處置收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.